How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, sex, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about erdafitinib

Marketing authorisation indication

2.1

Erdafitinib (Balversa, Johnson & Johnson) is indicated for 'the treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), harbouring susceptible FGFR3 genetic alterations who have previously received at least one line of therapy containing a PD‑1 or PD‑L1 inhibitor in the unresectable or metastatic treatment setting'.

Price

2.3

The list price for erdafitinib is £12,750 per 28 days (excluding VAT, company submission).

2.4

The company has a commercial arrangement, which would have applied if erdafitinib had been recommended.

Comments panel open